Valley National Advisers Inc. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,046 shares of the company’s stock after selling 183 shares during the period. Valley National Advisers Inc.’s holdings in Johnson & Johnson were worth $1,407,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Lincoln Capital Corp lifted its holdings in shares of Johnson & Johnson by 15.9% in the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after purchasing an additional 183 shares in the last quarter. Ieq Capital LLC lifted its stake in Johnson & Johnson by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after buying an additional 6,154 shares in the last quarter. RFG Advisory LLC grew its holdings in Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after buying an additional 594 shares during the last quarter. FDx Advisors Inc. increased its position in Johnson & Johnson by 0.3% during the third quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock worth $8,237,000 after buying an additional 153 shares in the last quarter. Finally, HM Payson & Co. raised its holdings in shares of Johnson & Johnson by 3.2% in the third quarter. HM Payson & Co. now owns 783,538 shares of the company’s stock worth $127,999,000 after acquiring an additional 24,188 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Stock Performance
Shares of NYSE:JNJ opened at $153.89 on Wednesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. Johnson & Johnson has a 12 month low of $150.71 and a 12 month high of $186.69. The firm has a market capitalization of $400.77 billion, a PE ratio of 22.83, a P/E/G ratio of 2.63 and a beta of 0.54. The business has a 50-day moving average of $161.11 and a two-hundred day moving average of $167.82.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were given a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.94%. Johnson & Johnson’s dividend payout ratio (DPR) is 67.06%.
Insider Activity at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.35% of the stock is owned by insiders.
Analyst Ratings Changes
JNJ has been the topic of a number of analyst reports. StockNews.com started coverage on Johnson & Johnson in a research note on Thursday, March 16th. They set a “strong-buy” rating on the stock. SVB Leerink lowered their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 25th. Atlantic Securities boosted their price target on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a report on Wednesday, January 25th. Finally, Guggenheim assumed coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $174.73.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Asana Stock Gap and Crap. Here’s Why
- On Holding AG Sprints Higher on Margin Expansion and Guidance
- Price Growth & Yield: For That Magical Combo, Leave the U.S.
- Game-Changing News For Tesla Investors
- DOW New Hghs Coming Sooner Than Later
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
